Survival outcomes (mPFS 8.2 months; 12-month OS 80.8%) compare favorably with typical first-line chemo-immunotherapy ...

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...

Week-18 ORR equivalence was achieved for HD204 vs reference bevacizumab (48.7% vs 46.5%), with both risk ratio and risk ...

In patients with marginal zone lymphoma (MZL), venetoclax (Venclexta) plus ibrutinib (Imbruvica) demonstrated safety and ...

Regulatory review timelines shifted from March 29 to June 29, 2026, after FDA requested more time to assess CMC/manufacturing ...

Theriva Biologics has received FDA agreement on the core design elements of a pivotal Phase 3 trial evaluating zabilugene ...

Relacorilant plus nab-paclitaxel achieved a 35% reduction in mortality risk with a 4.1-month median overall survival ...

Nadofaragene firadenovec-vncg is the only FDA-approved nonreplicating intravesical gene therapy for high-risk ...

Discover how CAR-T, bispecifics and gene therapy reshape cancer care—and what clinics need for safe, reimbursable outpatient ...

In an interview with Targeted Oncology, David Sallman, MD, of Moffitt Cancer Center, addresses the nuanced decision-making ...

Chemotherapy-induced myelosuppression (CIM) remains one of the most significant and underappreciated barriers to delivering ...

Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...